

09980652.102601

09/980652

JC10 Rec'd PCT/P10 2 6 OCT 2001

Docket No. 7202-220

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Fisch
Int'l App. No.: PCT/US01/15900 Int'l Filing Date: May 15, 2001
U.S. Serial No.: To Be Assigned Filing Date: Herewith
For: METHODS OF TREATING ANDROGEN DEFICIENCY IN MEN USING
SELECTIVE ANTIESTROGENS

Commissioner for Patents
Box PCT
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Prior to the examination of the above-identified application, please amend the application as follows.

In the claims:

Please add new claims 13 and 14 as shown below.

13. The method according to claim 3, wherein the clomiphene citrate comprises the cis isomer.
14. The method according to claim 3, wherein the clomiphene citrate comprises the trans isomer.

REMARKS

Claims 13 and 14 have been added. Claims 1-14 are now pending in this application, a copy of which is attached hereto.

Early and favorable consideration of this application is respectfully requested.

Respectfully submitted,

Dated: 10/26/01

Ira J. Schaefer
Reg. No. 26,802

MAILING ADDRESS:

Clifford Chance Rogers & Wells LLP
200 Park Avenue
New York, NY 10166-0153
(212) 878-4922

NYA 378308.1

PENDING CLAIMS

Applicant: Fisch

Int'l App. No.: PCT/US01/15900

Int'l Filing Date: May 15, 2001

Our Ref.: 7202-220

1. A method of treating androgen deficiency in men comprising administering a selective antiestrogen.
2. The method according to claim 1, wherein the selective antiestrogen is clomiphene.
3. The method according to claim 1, wherein the selective antiestrogen is clomiphene citrate.
4. A method of treating disorders related to male menopause in men comprising administering an antiestrogen.
5. The method according to claim 4, wherein the disorder is reduction of muscle mass.
6. The method according to claim 4, wherein the disorder is limitation of body performance capacity.
7. The method according to claim 4, wherein the disorder is reduction of bone density.
8. The method according to claim 4, wherein the disorder is reduction of libido.
9. The method according to claim 4, wherein the disorder is reduction of potency.
10. The method according to claim 4, wherein the disorder is reduction of benign prostatic hyperplasia.

PENDING CLAIMS

Applicant: Fisch

Int'l App. No.: PCT/US01/15900

Int'l Filing Date: May 15, 2001

Our Ref.: 7202-220

11. The method according to claim 1, wherein the selective antiestrogen is tamoxifen.
12. The method according to claim 1, wherein the selective antiestrogen is tamoxifen citrate.
13. The method according to claim 3, wherein the clomiphene citrate comprises the cis isomer.
14. The method according to claim 3, wherein the clomiphene citrate comprises the trans isomer.